首頁 > 市場調查報告書 > 製藥

精神疾病

全球抗焦慮藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

市場調查報告書

商品編碼

1421092

全球抗焦慮藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Anti-Anxiety Drug Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 139 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球抗焦慮藥物市場需求預計將從 2023 年的 157.4 億美元達到近 250.1 億美元的市場規模，2024-2032 年研究期間複合CAGR為 5.28%。

抗焦慮藥，也稱為抗焦慮藥，是一種旨在緩解焦慮症症狀的藥物。這些疾病是一種以過度擔憂、恐懼或緊張為特徵的精神健康狀況，通常會導致嚴重的痛苦或日常功能受損。這些藥物透過影響中樞神經系統來減輕焦慮症狀的強度。

市場動態

抗焦慮藥物市場是由幾個相互關聯的因素所推動的。全球對心理健康問題的認知和接受度不斷提高，加上焦慮症盛行率不斷上升，導致抗焦慮藥物的需求不斷成長。藥物研究和開發的不斷進步導致新化合物和製劑的發現，從而增強了這些藥物的有效性。全球人口老化的特徵是對焦慮症的敏感度更高，這進一步推動了市場的成長。此外，壓力水平升高的現代生活方式、不斷擴大的醫療基礎設施以及支持心理健康研究的不斷變化的監管環境都有助於市場的擴張。處方率的提高和遠距醫療和數位醫療等治療方式的技術進步也發揮關鍵作用。然而，挑戰包括對過度處方、潛在副作用的擔憂，以及需要包括治療和生活方式介入在內的全面心理健康方法。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球抗焦慮藥物市場的各個細分市場進行了包容性評估。抗焦慮藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

抗焦慮藥物市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按藥物類別

選擇性血清素再攝取抑制劑 (SSRI)
苯二氮平類
血清素-正腎上腺素再攝取抑制劑 (SNRI)
BETA受體阻斷劑

按配銷通路

醫院藥房
零售藥局/藥局
網路藥局

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲抗焦慮藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。抗焦慮藥物市場的主要參與者包括輝瑞公司、禮來公司、葛蘭素史克公司、強生公司、阿斯特捷利康公司、羅氏控股公司、森林實驗室（艾爾建的子公司，現為艾伯維的一部分）、百時美施貴寶施貴寶公司、賽諾菲公司、靈北公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：抗焦慮藥物公司的競爭格局

抗焦慮藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Eli Lilly and Company

公司簡介
公司收入
產品
最近的發展

GlaxoSmithKline plc

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson

公司簡介
公司收入
產品
最近的發展

AstraZeneca plc

公司簡介
公司收入
產品
最近的發展

Roche Holding AG

公司簡介
公司收入
產品
最近的發展

Forest Laboratories (a subsidiary of Allergan

公司簡介
公司收入
產品
最近的發展

now part of AbbVie)

公司簡介
公司收入
產品
最近的發展

Bristol Myers Squibb Company

公司簡介
公司收入
產品
最近的發展

Sanofi SA

公司簡介
公司收入
產品
最近的發展

Lundbeck A/S

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113495

The global demand for Anti-Anxiety Drug Market is presumed to reach the market size of nearly USD 25.01 Billion by 2032 from USD 15.74 Billion in 2023 with a CAGR of 5.28% under the study period 2024 - 2032.

Anti-anxiety drugs, also known as anxiolytics, are medications designed to relieve symptoms of anxiety disorders. These disorders are mental health conditions characterized by excessive worry, fear, or nervousness, often leading to significant distress or impairment in daily functioning. These drugs work by affecting the central nervous system to reduce the intensity of anxiety symptoms.

MARKET DYNAMICS

The anti-anxiety drug market is propelled by several interconnected factors. Rising global awareness and acceptance of mental health issues, coupled with an increasing prevalence of anxiety disorders, contribute to a growing demand for anti-anxiety medications. Ongoing advancements in pharmaceutical research and development lead to the discovery of novel compounds and formulations, enhancing the effectiveness of these medications. The aging global population, characterized by a higher susceptibility to anxiety disorders, further boosts market growth. Additionally, modern lifestyles with elevated stress levels, expanding healthcare infrastructure, and changing regulatory environments supporting mental health research contribute to the market's expansion. Increased prescription rates and technological advancements in treatment modalities, such as telemedicine and digital health, also play pivotal roles. However, challenges include concerns about over-prescription, potential side effects, and the need for a comprehensive mental health approach encompassing therapy and lifestyle interventions.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of anti-anxiety drug. The growth and trends of anti-anxiety drug industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the anti-anxiety drug market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Selective Serotonin Reuptake Inhibitors (SSRIs)
Benzodiazepines
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Beta Blockers

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies/Drug Stores
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Anti-Anxiety Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anti-Anxiety Drug market include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca plc, Roche Holding AG, Forest Laboratories (a subsidiary of Allergan, now part of AbbVie), Bristol Myers Squibb Company, Sanofi S.A., Lundbeck A/S. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ANTI-ANXIETY DRUG - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Selective Serotonin Reuptake Inhibitors (SSRIs) Historic and Forecast Sales by Regions
5.5 Benzodiazepines Historic and Forecast Sales by Regions
5.6 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Historic and Forecast Sales by Regions
5.7 Beta Blockers Historic and Forecast Sales by Regions

6 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1 Overview by Distribution Channel
6.2 Historical and Forecast Data
6.3 Analysis by Distribution Channel
6.4 Hospital Pharmacies Historic and Forecast Sales by Regions
6.5 Retail Pharmacies/Drug Stores Historic and Forecast Sales by Regions
6.6 Online Pharmacies Historic and Forecast Sales by Regions

7 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ANTI-ANXIETY DRUG COMPANIES

8.1. Anti-Anxiety Drug Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF ANTI-ANXIETY DRUG INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Pfizer Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Eli Lilly and Company
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. GlaxoSmithKline plc
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Johnson & Johnson
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. AstraZeneca plc
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Roche Holding AG
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Forest Laboratories (a subsidiary of Allergan
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. now part of AbbVie)
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Bristol Myers Squibb Company
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Sanofi S.A.
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
9.13. Lundbeck A/S
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表

LIST OF TABLES

Market Snapshot
Drivers : Impact Analysis
Restraints : Impact Analysis
List of Raw Material
List of Raw Material Manufactures
List of Potential Buyers
Analysis by Drug Class (USD MN)
Selective Serotonin Reuptake Inhibitors (SSRIs) Market Sales by Geography (USD MN)
Benzodiazepines Market Sales by Geography (USD MN)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Market Sales by Geography (USD MN)
Beta Blockers Market Sales by Geography (USD MN)
Analysis Market by Distribution Channel (USD MN)
Hospital Pharmacies Market Sales by Geography (USD MN)
Retail Pharmacies/Drug Stores Market Sales by Geography (USD MN)
Online Pharmacies Market Sales by Geography (USD MN)
Global Anti-Anxiety Drug Market Sales by Geography (USD MN)
North America Market Analysis (USD MN)
United State Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate by Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Anti-Anxiety Drug Report
Market Research Process
Market Research Methodology
Global Anti-Anxiety Drug Market Size, by Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis by Drug Class
Market Attractiveness Analysis by Distribution Channel
Market Attractiveness Analysis by Region
Value Chain Analysis
Global Market Analysis by Drug Class (USD MN)
Selective Serotonin Reuptake Inhibitors (SSRIs) Market Sales by Geography (USD MN)
Benzodiazepines Market Sales by Geography (USD MN)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Market Sales by Geography (USD MN)
Beta Blockers Market Sales by Geography (USD MN)
Global Market Analysis by Distribution Channel (USD MN)
Hospital Pharmacies Market Sales by Geography (USD MN)
Retail Pharmacies/Drug Stores Market Sales by Geography (USD MN)
Online Pharmacies Market Sales by Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Companies Market Share Analysis